Dexmedetomidine, Gastrointestinal Endoscopy, Sedation
Conditions
Brief summary
The objective of this study is to compare the efficacy and safety of dexmedetomidine with other sedatives in sedation during endoscopy by analyzing the most recently published interventional trials and observational studies.
Detailed description
A variety of sedatives are available in procedural sedation and the efficacy & safety have been compared in several trials for procedural sedation. However, none of clinical trial has enough number of patients to clarify the conclusive differences among sedatives. Thus, pooling all available studies together systematically by network meta-analysis for GI endoscopic procedure may provide a better understanding of efficacy and safety of sedatives. Therefore we would like to conduct a network meta-analysis to analyze the outcomes of GI endoscopy by using the most recently-published interventional trials.
Interventions
DRUGDexmedetomidine
Dexmedetomidine group
DRUGMidazolam
Midazolam group
DRUGPropofol
Propofol group
DRUGMidazolam/Propofol
Midazolam/Propofol group
Sponsors
Pfizer
Study design
Observational model
OTHER
Time perspective
OTHER
Eligibility
Sex/Gender
ALL
Age
12 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Inclusion criteria We will include studies if they (1) the setting was using any sedative for endoscopy for an procedural sedation (2) the study compared dexmedetomidine with other sedative for sedative therapy and (3) the outcomes included satisfaction score and adverse events. *
Exclusion criteria
We excluded studies if they (1) the number of sedative was different in two arms (2) did not report the specific results comparing dexmedetomidine with other sedatives.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Number of subjects who experience desaturation | From first infusion of the sedative agent until awakening approximately up to 2 hours after the procedure. | SaO2 \< 94% for more than 10 seconds, RR\<8, apneic episodes, face mask |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Number of subjects who experience Hypotension | From first infusion of the sedative agent until awakening approximately up to 2 hours after the procedure | BP\<90/50, decrease\>20% or 10mmHg, MAP\<60mmHg or MAP decrease\>20% |
| Number of subjects who experience Bradycardia | From first infusion of the sedative agent until awakening approximately up to 2 hours after the procedure | A heart rate of \<50 beats per min, decrease \> 15% |
Countries
South Korea
Outcome results
None listed